Recent Highlights
All Stories for Covaxin Vaccine
Bharat Biotech seeks approval for Covaxin in US for children below 18 years
• 3 years agoClinical trials were conducted on 526 kids during which no serious adverse events or hospitalisations were observed
Bharat Biotech's COVAXIN has 77.8% efficacy in Phase 3 trials, says report: All you need to know
Fp Staff • 4 years agoThe data will be reviewed by the WHO on 23 June in a 'pre-submission meeting', and COVAXIN will be allowed for export to other countries only after an approval from the global health body
Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021
• 4 years agoRaches Ella, project lead COVID-19 Vaccines at Bharat Biotech said that there were nine publications on Covaxin so far and the efficacy paper on Phase-3 trials would be the tenth one
Joe Biden announces COVID-19 vaccine sharing plan: US to send 25 million jabs around world
• 4 years agoThe White House said around 19 million will go to UN-backed program COVAX, with approximately 6 million for South and Central America, 7 million for Asia and 5 million for Africa
Increase gap between Covishield vaccine doses to 4-8 weeks, Centre tells states
• 4 years agoThis decision to revise the interval between doses from 4-6 weeks is applicable only to Covishield and not to Covaxin, the Union health ministry said
Covaxin phase 2 data shows vaccine safe, induces immune response, says Lancet study
• 4 years agoThe authors of the study noted that the phase 2 results did not assess the efficacy of the vaccine codenamed BBV152
Covaxin jab effective against UK variant of coronavirus, claims study
• 4 years agoCovaxin - vaccine developed by Hyderabad-based Bharat Biotech - is effective against UK variants of COVID-19, according to a study on 26 participants, shared by the company on Wednesday.